Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Nicolini · SciRah

Researcher profile · Semantic Scholar

F. Nicolini

Share profile

F. Nicolini — researcher profile on SciRah

h-index: 57
Works: 514
Citations: 17K

Most-cited papers

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer +30 more
2020Leukemia1,342 citations Open access
Semantic Scholar
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
N. Shah, V. García-Gutiérrez, A. Jiménez-Velasco, Sarah M. Larson +11 more
2020Leukemia and Lymphoma130 citations Open access
Semantic Scholar
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
F. Nicolini, S. Dulucq, L. Boureau, P. Cony-Makhoul +29 more
2019Clinical Cancer Research103 citations
Semantic Scholar
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
J. Rohmer, A. Couteau-Chardon, J. Trichereau, Kewin Panel +34 more
2020American journal of hematology/oncology65 citations
Semantic Scholar
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
F. Mahon, M. Pfirrmann, S. Dulucq, A. Hochhaus +23 more
2024Journal of Clinical Oncology60 citations Open access
Semantic Scholar
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
J. Januzzi, Joseph M. Garasic, S. Kasner, V. Mcdonald +17 more
2022Journal of Hematology & Oncology53 citations Open access
Semantic Scholar
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
H. Kantarjian, E. Jabbour, Michael W. Deininger, E. Abruzzese +17 more
2022American journal of hematology/oncology49 citations Open access
Semantic Scholar
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
P. Rousselot, L. Mollica, J. Guilhot, A. Guerci +21 more
2021British Journal of Haematology47 citations Open access
Semantic Scholar
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update
T. Hughes, N. Clementino, M. Fominykh, J. Lipton +10 more
2021Leukemia47 citations Open access
Semantic Scholar
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
A. Kizilors, E. Crisà, N. Lea, R. Passera +20 more
2019The Lancet Haematology46 citations
Semantic Scholar
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
E. Jabbour, J. Apperley, J. Cortes, D. Réa +16 more
2024Leukemia43 citations Open access
Semantic Scholar
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
M. Berger, Bruno Pereira, P. Rousselot, P. Cony-Makhoul +12 more
2019British Journal of Haematology40 citations
Semantic Scholar
Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib
J. Cortes, T. Saikia, Dong-Wook Kim, Y. Alvarado +20 more
202032 citations Open access
Semantic Scholar
The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission
S. Jeanpierre, Kawtar Arizkane, S. Thongjuea, Élodie Grockowiak +10 more
2020Haematologica32 citations Open access
Semantic Scholar
Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation
L. Bondeelle, Julien Gras, D. Michonneau, V. Houdouin +12 more
2019Bone Marrow Transplantation32 citations
Semantic Scholar
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Rahul Kumar, Raquel S. Pereira, C. Zanetti, Valentina R. Minciacchi +16 more
2020Leukemia29 citations Open access
Semantic Scholar
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study
S. Dulucq, F. Rigal-huguet, F. Nicolini, P. Cony-Makhoul +15 more
2023British Journal of Haematology21 citations Open access
Semantic Scholar
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
H. Johnson-Ansah, B. Manéglier, F. Huguet, L. Legros +22 more
2022Pharmaceutics20 citations Open access
Semantic Scholar
MANGANESE deficiency.
M. Oette, M. Stone, H. Scholl, P. Issa +175 more
2022Journal of the American Veterinary Medical Association20 citations Open access
Semantic Scholar
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
S. Dulucq, F. Nicolini, D. Réa, P. Cony-Makhoul +26 more
2022Haematologica20 citations Open access
Semantic Scholar
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
Alexis Genthon, F. Nicolini, F. Huguet, Carole Colin-Gil +10 more
2020OncoTarget19 citations Open access
Semantic Scholar
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience
M. Heiblig, H. Labussière-Wallet, F. Nicolini, M. Michallet +11 more
2019Cancers17 citations Open access
Semantic Scholar
Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial
F. Nicolini, G. Étienne, F. Huguet, A. Guerci-Bresler +25 more
2021Blood14 citations
Semantic Scholar
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
A. Burchert, S. Saussele, Christian Michel, S. Metzelder +30 more
2022Blood13 citations Open access
Semantic Scholar
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
S. Dulucq, S. Hayette, J. Cayuela, F. Bauduer +13 more
2022Haematologica13 citations Open access
Semantic Scholar
Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
H. Kantarjian, M. Deininger, E. Abruzzese, J. Apperley +16 more
202013 citations Open access
Semantic Scholar
Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
P. Dumas, Emilie Bérard, C. Bréal, S. Dulucq +12 more
2019Cancer Medicine13 citations Open access
Semantic Scholar
Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study)
L. Roy, J. Chomel, J. Guilhot, A. Guerci-Bresler +23 more
2022British Journal of Haematology12 citations
Semantic Scholar
P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
J. Apperley, H. Kantarjian, M. Deininger, E. Abruzzese +17 more
2022HemaSphere12 citations Open access
Semantic Scholar
Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Jorge E. Cortes, T. Saikia, Dong-Wook Kim, Y. Alvarado +22 more
2022Blood12 citations Open access
Semantic Scholar
Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies
S. Hayette, Béatrice Grange, M. Vallée, C. Bardel +11 more
2021HemaSphere11 citations Open access
Semantic Scholar
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy
A. Decroos, S. Meddour, Marine Demoy, Nathalie Piccirilli +7 more
2024Frontiers in Immunology10 citations Open access
Semantic Scholar
FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study
F. Mahon, J. Richter, A. Hochhaus, P. Panayiotidis +16 more
2021Blood10 citations Open access
Semantic Scholar
[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
J. Cayuela, J. Chomel, V. Coiteux, S. Dulucq +8 more
2020Bulletin du Cancer9 citations Open access
Semantic Scholar
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
G. Zambrotta, F. Nicolini, S. Assouline, L. Busque +24 more
2023American journal of hematology/oncology8 citations Open access
Semantic Scholar
Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France
A. Belhabri, M. Heiblig, S. Morisset, L. Vila +18 more
2023Cancer Medicine6 citations Open access
Semantic Scholar
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
F. Nicolini, F. Huguet, L. Huynh, Churong Xu +3 more
2023Cancers6 citations Open access
Semantic Scholar
Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials
E. Jabbour, M. Deininger, E. Abruzzese, J. Apperley +17 more
2021Blood6 citations Open access
Semantic Scholar
COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study
K. Pagnano, C. Kok, M. Mauro, Jorge E. Cortes +9 more
2021Blood5 citations Open access
Semantic Scholar
Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM
V. Julien, D. Réa, S. Thepot, L. P. Bruno +10 more
2019Blood5 citations Open access
Semantic Scholar
Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
C. Orvain, S. Tavitian, Clémence Médiavilla, Françoise Boyer +29 more
2025HemaSphere4 citations Open access
Semantic Scholar
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
G. Étienne, D. Réa, V. Coiteux, A. Guerci-Bresler +4 more
2021Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis4 citations
Semantic Scholar
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
J. Januzzi, Joseph M. Garasic, S. Kasner, V. Mcdonald +16 more
20204 citations
Semantic Scholar
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
M. Balsat, V. Alcazer, G. Étienne, F. Huguet +19 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis3 citations Open access
Semantic Scholar
Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy
M. Perusini, Camille Kockerols, Daniela Žáčková, F. Nicolini +15 more
2023Blood3 citations
Semantic Scholar
Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study
F. Nicolini, E. Abruzzese, G. Roth-Guepin, Rami Abi-Tayeh +7 more
2023Blood3 citations
Semantic Scholar
A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53WT, Ph+ Chronic Myeloid Leukemia
J. Cortes, Omer H. Jamy, Guillermo Ortí, F. Prósper +4 more
2021Blood3 citations
Semantic Scholar
ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia
F. Mahon, Nelma D. Clementino, M. Fominykh, J. Lipton +10 more
20203 citations Open access
Semantic Scholar
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line
S. Dulucq, G. Étienne, S. Morisset, E. Klein +7 more
2019Annals of Hematology3 citations Open access
Semantic Scholar
Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study
C. Orvain, S. Tavitian, Clémence Médiavilla, Françoise Boyer +27 more
2024Blood2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Réa×23
Invite
D. Réa — researcher profile on SciRah
F. Mahon×17
Invite
F. Mahon — researcher profile on SciRah
G. Étienne×14
Invite
G. Étienne — researcher profile on SciRah
P. Rousselot×13
Invite
P. Rousselot — researcher profile on SciRah

×13

Invite

L. Legros — researcher profile on SciRah

Invite

M. Mauro — researcher profile on SciRah

P. Cony-Makhoul×11

Invite

P. Cony-Makhoul — researcher profile on SciRah

Invite

S. Dulucq — researcher profile on SciRah

M. Escoffre-barbe×10

Invite

M. Escoffre-barbe — researcher profile on SciRah

Invite

A. Hochhaus — researcher profile on SciRah

Invite

S. Hayette — researcher profile on SciRah

A. Charbonnier×8

Invite

A. Charbonnier — researcher profile on SciRah